Expression of the prostate cancer metastasis suppressor geneKAI1 in primary prostate cancers: a biphasic relationship with tumour grade

1999 ◽  
Vol 188 (4) ◽  
pp. 382-388 ◽  
Author(s):  
Toula Bouras ◽  
Albert G. Frauman
Keyword(s):  
Prostate Cancer ◽  
Cancer Metastasis ◽  
Metastasis Suppressor ◽  
Tumour Grade ◽  
Prostate Cancer Metastasis ◽  
Prostate Cancers

scholarly journals RIPK2 Stabilizes c-Myc and is an Actionable Target for Inhibiting Prostate Cancer Metastasis

2020 ◽  
Author(s):  
Yiwu Yan ◽  
Bo Zhou ◽  
Chen Qian ◽  
Alex Vasquez ◽  
Avradip Chatterjee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Drug Targets ◽  
Cancer Metastasis ◽  
Therapeutic Interventions ◽  
Interacting Protein ◽  
Prostate Cancer Metastasis ◽  
Prostate Cancers

AbstractDespite advances in diagnosis and treatment, metastatic prostate cancer remains incurable and is associated with high mortality rates. Thus, novel actionable drug targets are urgently needed for therapeutic interventions in advanced prostate cancer. Here we report receptor-interacting protein kinase 2 (RIPK2) as an actionable drug target for suppressing prostate cancer metastasis. RIPK2 is frequently amplified in lethal prostate cancers and its overexpression is associated with disease progression and aggressiveness. Genetic and pharmacological inhibition of RIPK2 significantly suppressed prostate cancer progression in vitro and metastasis in vivo. Multi-level proteomic analysis revealed that RIPK2 strongly regulates c-Myc protein stability and activity, largely by activating the MKK7/JNK/c-Myc phosphorylation pathway—a novel, non-canonical RIPK2 signaling pathway. Targeting RIPK2 inhibits this phosphorylation pathway, and thus promotes the degradation of c-Myc—a potent oncoprotein for which no drugs have been approved for clinical use yet. These results support targeting RIPK2 for personalized therapy in prostate cancer patients towards improving survival.

Localization of prostate cancer metastasis-suppressor activity on human chromosome 17

The Prostate ◽  
1997 ◽  
Vol 33 (4) ◽  
pp. 271-280 ◽  
Author(s):  
Marina A. Chekmareva ◽  
Courtney M.P. Hollowell ◽  
Robert C. Smith ◽  
Elizabeth M. Davis ◽  
Michelle M. LeBeau ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Human Chromosome ◽  
Cancer Metastasis ◽  
Chromosome 17 ◽  
Metastasis Suppressor ◽  
Suppressor Activity ◽  
Prostate Cancer Metastasis ◽  
Human Chromosome 17

scholarly journals m6A Methylation Regulators Are Predictive Biomarkers for Tumour Metastasis in Prostate Cancer

2020 ◽  
Author(s):  
Xiaobo Wu ◽  
Qianwen Ge ◽  
Chen Yang ◽  
Yishuo Wu ◽  
Mengbo Hu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Cancer Metastasis ◽  
Immune Cell ◽  
Cell Infiltration ◽  
Immune Cell Infiltration ◽  
Consensus Clustering ◽  
Prostate Cancer Progression ◽  
Prostate Cancer Metastasis ◽  
Prostate Cancers

Abstract BackgroundProstate cancer is one of the most common cancers in men. Usually, most prostate cancers are localized in initial diagnoses and grow slowly. Patients with localized prostate cancers have a nearly 100% 5-year survival rate; however, the 5-year survival rate of metastatic or progressive prostate cancer is still dismal. N6-methyladenosine (m6A) is the most common post-transcriptional mRNA modification and is dynamically regulated by m6A regulators. A few studies have shown that the abnormal expression of m6A regulators is significantly associated with cancer progression and immune cell infiltration, but the roles of these regulators in prostate cancer remain unclear. MethodsHere, we comprehensively examined the patterns of 21 m6A regulators across 494 prostate cancers and systematically correlated m6A regulators with prostate cancer progression and immune cell infiltration. Consensus clustering was utilized for the subtype identification of m6A regulators for prostate cancers. Each subtype signature genes were obtained by the pairwise differentially expressed genes. Featured pathways of m6A subtypes were predicted consequently. The m6A score was constructed to predict the m6A activation. The association of m6A score with patients’ survival, metastasis and immune cell infiltration were also investigated. ResultsWe identified three distinct clusters in prostate cancer based on the expression profiles of 21 m6A regulators by consensus clustering. The differential expression and pathway analyses on the three clusters uncovered the m6A regulators involved in metabolic processes and immune responses in prostate cancer. Moreover, we established an m6A score to perceive the m6A regulator activation for prostate cancer. The m6A score is significantly associated with Gleason scores and metastasis in prostate cancer. The predictive capacity of m6A score on prostate cancer metastasis was also validated in another independent cohort. ConclusionOur study revealed the critical role of m6A regulators in prostate cancer progression and m6A score is promising predictive biomarker for prostate cancer metastasis.

scholarly journals A solitary hypothalamic metastasis from prostatic cancer mimicking a giant thrombotic aneurysm and presenting with intraventricular hemorrhage and acute hydrocephalus: a case report

2020 ◽  
Vol 51 (1) ◽  
Author(s):  
Zarhra Saadatpour ◽  
Ali Rezaei ◽  
Aparna Singhal ◽  
Houman Sotoudeh ◽  
Kamran Tavakol
Keyword(s):  
Prostate Cancer ◽  
Intraventricular Hemorrhage ◽  
Cancer Metastasis ◽  
Giant Aneurysm ◽  
Motor Deficit ◽  
Acute Hydrocephalus ◽  
Suprasellar Region ◽  
Prostate Cancer Metastasis ◽  
Prostate Cancers ◽  
Brain Parenchymal

Abstract Background Despite the high prevalence of prostate cancer, its brain parenchymal metastasis is not common and intracranial hemorrhage due to such a metastasis is even less common. This report presents a challenging case of solitary brain metastasis secondary to prostate cancer that gave rise to intraventricular hemorrhage and acute hydrocephalus mimicking a giant aneurysm. Case presentation A 77-year-old man with a history of prostate cancer, hypertension, and morbid obesity presented to the emergency room with a severe headache. He was afebrile with a blood pressure of 144/79 mmHg, alert, without any sign of sensory or motor deficit. Shortly after admission, he became unresponsive and was immediately intubated. His blood tests revealed hypernatremia at 154 mmol/L; otherwise, the lab data including the COVID-19 screening proved normal. The cerebral CT and MR images, with and without contrast, were interpreted as a giant thrombotic aneurysm extending to the suprasellar region by the emergency radiologist. Also, moderate intraventricular hemorrhage, acute hydrocephalus, and sub-ependymal interstitial edema were observed. Upon further evaluation of the images, the lesion was determined to be an exophytic hemorrhagic hypothalamic mass, and the subsequent biopsy was consistent with prostate cancer metastasis. Conclusions The exophytic hemorrhagic hypothalamic metastasis can mimic a ruptured aneurysm on imaging. Given the improved survival of patients with prostate cancer, radiologists may encounter such unusual cerebral metastases from prostate cancers more frequently in the future.

Sign in / Sign up

Export Citation Format

Share Document